Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of “Buy” by Brokerages

Avalyn Pharma Inc. (NASDAQ:AVLN) has received a consensus recommendation of “Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $59.00.

AVLN has been the topic of a number of research analyst reports. Guggenheim initiated coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target on the stock. Evercore initiated coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “outperform” rating and a $51.00 price target on the stock. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $52.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target on the stock.

Avalyn Pharma Stock Up 5.9%

Shares of AVLN opened at $28.39 on Friday. Avalyn Pharma has a 12 month low of $25.05 and a 12 month high of $32.22.

Insiders Place Their Bets

In related news, Director Jill Carroll acquired 277,778 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.